MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

Search

Boston Scientific Corp.

Затворен

СекторЗдравеопазване

100.77 1.39

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

97.82

Максимум

101.18

Ключови измерители

By Trading Economics

Приходи

-138M

562M

Продажби

352M

4.6B

P/E

Средно за сектора

82.136

73.239

EPS

0.7

Марж на печалбата

12.322

Служители

53,000

EBITDA

-41M

1B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+20.2% upside

Дивиденти

By Dow Jones

Следващи печалби

23.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-250M

152B

Предишно отваряне

99.38

Предишно затваряне

100.77

Настроения в новините

By Acuity

40%

60%

126 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Boston Scientific Corp. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.03.2025 г., 12:35 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5.02.2025 г., 12:23 ч. UTC

Печалби

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

8.01.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Rest of Bolt Medical for $443 Million

4.11.2024 г., 13:01 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Medical-Technology Company Cortex

3.03.2025 г., 11:59 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3.03.2025 г., 11:58 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3.03.2025 г., 11:58 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5.02.2025 г., 21:33 ч. UTC

Печалби

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5.02.2025 г., 15:20 ч. UTC

Печалби

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5.02.2025 г., 11:39 ч. UTC

Печалби

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5.02.2025 г., 11:39 ч. UTC

Печалби

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5.02.2025 г., 11:38 ч. UTC

Печалби

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5.02.2025 г., 11:38 ч. UTC

Печалби

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q Adj EPS 70c >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q Sales $4.56B >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q EPS 38c >BSX

8.01.2025 г., 12:10 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Sees Deal More Dilutive on GAAP Basis >BSX

8.01.2025 г., 12:09 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Sees Deal Slightly Dilutive to Adj EPS in 2025 >BSX

8.01.2025 г., 12:09 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Pay Up to Another $221M After Certain Regulatory Milestones >BSX

8.01.2025 г., 12:08 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Deal Includes Upfront Payment of About $443M for 74% Stake Not yet Owned >BSX

8.01.2025 г., 12:07 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Buyout to Further Co's Strategy to Address Coronary and Peripheral Disease >BSX

8.01.2025 г., 12:07 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Buyout to Expand Cardiovascular Portfolio With Complementary, Differentiated Calcium Modification Platform >BSX

8.01.2025 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Announces Agreement To Acquire Bolt Medical, Inc. >BSX

25.11.2024 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Announces Agreement To Acquire Intera Oncology(R) Inc. >BSX

15.11.2024 г., 13:43 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Closes Acquisition Of Axonics, Inc. >BSX AXNX

Сравнение с други в отрасъла

Ценова промяна

Boston Scientific Corp. Прогноза

Ценова цел

By TipRanks

20.2% нагоре

12-месечна прогноза

Среден 119.43 USD  20.2%

Висок 135 USD

Нисък 100 USD

Според 24 анализатори от Wall Street, предложили 12-месечна ценова цел за Boston Scientific Corp. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

24 ratings

23

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

99.22 / 101Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

126 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.